Dr. Chase on Toxicities of Treatments for Ovarian Cancer

Dana M. Chase, MD, FACOG
Published: Friday, Apr 21, 2017



Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologist oncologist with Arizona Oncology, discusses the toxicity profiles and managing side effects of treatments for patients with recurrent ovarian cancer.

The biggest side effect of paclitaxel, one of the most commonly used drugs for ovarian cancer, is hair loss, explains Chase. When combined with carboplatin, paclitaxel can also cause fatigue and neuropathy. Nausea and vomiting are also common side effects with various other chemotherapy regimens.

Bevacizumab (Avastin) is a very well-tolerated drug and most of the toxicities are manageable. There are medications to manage the hypertension allowing bevacizumab to be taken long term, states Chase.



Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologist oncologist with Arizona Oncology, discusses the toxicity profiles and managing side effects of treatments for patients with recurrent ovarian cancer.

The biggest side effect of paclitaxel, one of the most commonly used drugs for ovarian cancer, is hair loss, explains Chase. When combined with carboplatin, paclitaxel can also cause fatigue and neuropathy. Nausea and vomiting are also common side effects with various other chemotherapy regimens.

Bevacizumab (Avastin) is a very well-tolerated drug and most of the toxicities are manageable. There are medications to manage the hypertension allowing bevacizumab to be taken long term, states Chase.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x